James M Angelastro
Overview
Explore the profile of James M Angelastro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
893
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ore A, Angelastro J, Giulivi C
Brain Sci
. 2024 Sep;
14(9).
PMID: 39335395
The role of mitochondria in neurodegenerative diseases is crucial, and recent developments have highlighted its significance in cell therapy. Mitochondrial dysfunction has been implicated in various neurodegenerative disorders, including Alzheimer's,...
2.
Banerjee D, Boboila S, Okochi S, Angelastro J, Kadenhe-Chiweshe A, Lopez G, et al.
Cancer Res Commun
. 2023 Nov;
3(12):2518-2530.
PMID: 38014922
Significance: This study shows that resistance to anoikis in neuroblastoma is mediated by ATF5 and offers a rationale for targeting ATF5 to treat metastatic neuroblastoma.
3.
Dreyer C, VanderVorst K, Natwick D, Bell G, Sood P, Hernandez M, et al.
Cancer Lett
. 2023 Jun;
567:216280.
PMID: 37336284
Targeting common oncogenic drivers of glioblastoma multiforme (GBM) in patients has remained largely ineffective, raising the possibility that alternative pathways may contribute to tumor aggressiveness. Here we demonstrate that Vangl1...
4.
Greene L, Zhou Q, Siegelin M, Angelastro J
Cells
. 2023 Feb;
12(4).
PMID: 36831248
Developing novel therapeutics often follows three steps: target identification, design of strategies to suppress target activity and drug development to implement the strategies. In this review, we recount the evidence...
5.
Zhou Q, Sun X, Pasquier N, Jefferson P, Nguyen T, Siegelin M, et al.
Cancers (Basel)
. 2021 Jun;
13(10).
PMID: 34065488
Transcription factors are key players underlying cancer formation, growth, survival, metastasis and treatment resistance, yet few drugs exist to directly target them. Here, we characterized the in vitro and in...
6.
Datta S, Sears T, Cortopassi G, Woolard K, Angelastro J
Biomed Pharmacother
. 2020 Dec;
133:111058.
PMID: 33378970
Glioblastoma Multiforme (GBM) tumors contain a small population of glioma stem-like cells (GSCs) among the various differentiated GBM cells (d-GCs). GSCs drive tumor recurrence, and resistance to Temozolomide (TMZ), the...
7.
Sandoval J, Tomilov A, Datta S, Allen S, ODonnell R, Sears T, et al.
Pharmaceuticals (Basel)
. 2020 Dec;
13(12).
PMID: 33255358
Glioblastoma (GBM) is an aggressive tumor of the brain, with an average post-diagnosis survival of 15 months. GBM stem cells (GBMSC) resist the standard-of-care therapy, temozolomide, and are considered a...
8.
Hua Z, Hansen J, He M, Dai S, Choi Y, Fulton M, et al.
Oncogenesis
. 2020 May;
9(5):50.
PMID: 32415090
Aberrant expression of protein arginine methyltransferases (PRMTs) has been implicated in a number of cancers, making PRMTs potential therapeutic targets. But it remains not well understood how PRMTs impact specific...
9.
Sun X, Jefferson P, Zhou Q, Angelastro J, Greene L
Mol Cancer Res
. 2019 Nov;
18(2):216-228.
PMID: 31676720
The basic leucine zipper transcription factor ATF5 is overexpressed in many tumor types and interference with its expression or function inhibits cancer cell survival. As a potential therapeutic approach to...
10.
Allen S, Datta S, Sandoval J, Tomilov A, Sears T, Woolard K, et al.
Mitochondrion
. 2019 Oct;
50:19-24.
PMID: 31654752
AMP-activated protein kinase (AMPK) is a eukaryotic energy sensor and protector from mitochondrial/energetic stress that is also a therapeutic target for cancer and metabolic disease. Metformin is an AMPK inducer...